Back to news

Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer

PR Newswire•19/11/2026•07:00 ET
1

Key Highlights

  • ➤50% of 10 NSCLC cell lines showed primary resistance to TUSC2 gene delivery
  • ➤50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery
  • ➤Low TROP2 expression consistently marked resistance across multiple preclinical models
  • ➤Pretreatment biopsy analysis supported TROP2 expression’s association with treatment response
  • ➤TROP2 modulation significantly increased NSCLC sensitivity to TUSC2 gene therapy

Expert Statements

Ryan Confer, President and Chief Executive Officer of Genprex

“Identifying which patients are most likely to benefit from REQORSA is one of the most important steps we can take to advance precision oncology”

Ryan Confer, President and Chief Executive Officer of Genprex

“These data suggest that TROP2 may help us identify which patients will benefit the most from REQORSA.”

Ryan Confer, President and Chief Executive Officer of Genprex

“These findings were supported across cell lines, patient-derived organoids and tumor models and in pretreatment biopsies from patients in our clinical program.”

Ryan Confer, President and Chief Executive Officer of Genprex

“Additionally, we are encouraged to see that TROP2 may do more than predict patient response.”

Ryan Confer, President and Chief Executive Officer of Genprex

“Our collaborators found that modulating TROP2 levels changes how cancer cells responded to REQORSA.”

Ryan Confer, President and Chief Executive Officer of Genprex

“We look forward to continuing to explore how TROP2 could help inform patient selection, and even potentially enhance REQORSA treatment, in future studies.”

Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer PR Newswire

Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance Efficacy

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in